CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices
This article was originally published in The Gray Sheet
Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.
You may also be interested in...
After spending the past six months receiving and reviewing hundreds of product applications, US FDA has decided to select eight promising devices and diagnostics to help tackle the opioid crisis.
Companies want FDA to expand the bounds of its accelerated device development program, while others urge FDA to be cautious.
The newly proposed “expedited access” PMA program combines early and outsized interactions between reviewers and manufacturers with the promise of lightened premarket requirements for selected products – if the potential pay off to patients is large enough and postmarket controls are sufficient.